Insulet Corp

Затворен

СекторЗдравеопазване

141.07 1.31

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

130

Максимум

139.41

Ключови измерители

By Trading Economics

Приходи

-11M

91M

Продажби

-22M

762M

P/E

Средно за сектора

39.65

68.51

EPS

1.42

Марж на печалбата

11.96

Служители

5,400

EBITDA

-23M

154M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+30.91% upside

Дивиденти

By Acuity

Следващи печалби

5.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-117M

12B

Предишно отваряне

139.76

Предишно затваряне

141.07

Настроения в новините

By Acuity

74%

26%

310 / 340 Класиране в Healthcare

Insulet Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 23:32 ч. UTC

News

Insulet Corp shares are lower in after-market hours following a downgrade to Market Perform by Leerink Partners and a reduced price target of $145.

5.08.2026 г., 23:46 ч. UTC

Insulet Corp. shares traded lower in after-market hours, reflecting routine activity and cautious market sentiment amid disappointing private sector employment data.

4.08.2026 г., 23:56 ч. UTC

Insulet Corp shares are lower in after-market hours, showing little change since Tuesday's close amid a lack of specific company news.

3.08.2026 г., 19:36 ч. UTC

Correlated Moves

Insulet Corp's shares are higher today, supported by a positive trend in the medical devices sector. The stock remains above its 20-day moving average.

31.07.2026 г., 20:06 ч. UTC

News

Insulet Corp shares are declining amid a securities class action lawsuit alleging misrepresentations about the safety of its Omnipod products.

29.07.2026 г., 18:43 ч. UTC

Insulet Corp shares are higher, driven by gains in the Health Care Equipment sub-sector. The stock remains well above its 20-day moving average.

28.07.2026 г., 19:06 ч. UTC

Correlated Moves

Insulet Corp shares are trading higher, benefiting from a significant rise in the Health Care Equipment sub-sector and ongoing momentum above their 20-day moving average.

27.07.2026 г., 20:06 ч. UTC

Insulet Corp shares are higher today, reflecting broader market trends despite an earlier pullback from a session high. No specific news was identified.

24.07.2026 г., 22:26 ч. UTC

Insulet Corp shares are lower in after-market hours, following a decline from earlier session lows. No specific company news was identified to explain the movement.

22.07.2026 г., 20:01 ч. UTC

News

Insulet Corp shares are lower amid a class action lawsuit alleging securities fraud related to safety claims about its Omnipod products.

20.07.2026 г., 18:36 ч. UTC

News

Insulet Corp is gaining today after being identified as a healthcare stock likely to deliver sustainable market-beating returns, despite ongoing legal challenges.

Сравнение с други в отрасъла

Ценова промяна

Insulet Corp Прогноза

Ценова цел

By TipRanks

30.91% нагоре

12-месечна прогноза

Среден 174.45 USD  30.91%

Висок 216 USD

Нисък 144 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за Insulet Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

23 ratings

13

Купи

9

Задържане

1

Продай

Настроение

By Acuity

310 / 340 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat